International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature
T Günther, G Tulipano, P Dournaud, C Bousquet… - Pharmacological …, 2018 - ASPET
Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …
Somatostatin receptors: from signaling to clinical practice
M Theodoropoulou, GK Stalla - Frontiers in neuroendocrinology, 2013 - Elsevier
Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …
invaluable drug target for the pharmacological management of pituitary adenomas and …
Epidemiology of acromegaly
IM Holdaway, C Rajasoorya - Pituitary, 1999 - Springer
Acromegaly was defined as a syndrome by Pierre Marie in 1885, but in the form of either
acromegaly or acrogigantism has probably been a disorder of antiquity [1, 2]. It is one of the …
acromegaly or acrogigantism has probably been a disorder of antiquity [1, 2]. It is one of the …
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families
Context: An association between germline aryl hydrocarbon receptor-interacting protein
(AIP) gene mutations and pituitary adenomas was recently shown. Objective: The objective …
(AIP) gene mutations and pituitary adenomas was recently shown. Objective: The objective …
Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly
BE Hayward, A Barlier, M Korbonits… - The Journal of …, 2001 - Am Soc Clin Investig
Approximately 40% of growth hormone–secreting pituitary adenomas have somatic
mutations in the GNAS1 gene (the so-called gsp oncogene). These mutations at codon 201 …
mutations in the GNAS1 gene (the so-called gsp oncogene). These mutations at codon 201 …
Somatostatin receptor ligands in the treatment of acromegaly
First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical
treatment of acromegaly, however the percentage of patients controlled with these drugs …
treatment of acromegaly, however the percentage of patients controlled with these drugs …
Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly
SL Fougner, O Casar‐Borota, A Heck… - Clinical …, 2012 - Wiley Online Library
Context Somatotroph adenomas have been classified into densely granulated (DG) and
sparsely granulated (SG) tumours with a transitional, intermediate group. Gsp oncogenes …
sparsely granulated (SG) tumours with a transitional, intermediate group. Gsp oncogenes …
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of …
M Mercado, F Borges, H Bouterfa… - Clinical …, 2007 - Wiley Online Library
Objective To evaluate the efficacy, safety and tolerability of octreotide LAR®(long‐acting
repeatable octreotide) in the primary therapy of acromegaly. Design and patients Ninety …
repeatable octreotide) in the primary therapy of acromegaly. Design and patients Ninety …
60 years of neuroendocrinology: acromegaly
C Capatina, JAH Wass - Journal of Endocrinology, 2015 - joe.bioscientifica.com
Acromegaly (ACM) is a chronic, progressive disorder caused by the persistent
hypersecretion of GH, in the vast majority of cases secreted by a pituitary adenoma. The …
hypersecretion of GH, in the vast majority of cases secreted by a pituitary adenoma. The …
Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs …
Context: Somatostatin receptor subtype 2 (sst2A) protein expression has been demonstrated
to positively correlate with somatostatin analog treatment outcome in GH-secreting …
to positively correlate with somatostatin analog treatment outcome in GH-secreting …